Premium
MAGNESIUM ADMINISTRATION REVERSES THE HYPOCALCAEMIA SECONDARY TO HYPOMAGNESAEMIA DESPITE LOW CIRCULATING LEVELS OF 25‐HYDROXYVITAMIN D AND 1,25‐DIHYDROXY VITAMIN D
Author(s) -
FUSS M.,
COGAN E.,
GILLET C.,
KARMALI R.,
GEURTS J.,
BERGANS A.,
BRAUMAN H.,
BOUILLON R.,
CORVILAIN J.
Publication year - 1985
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1985.tb00171.x
Subject(s) - hypocalcaemia , medicine , endocrinology , parathyroid hormone , magnesium , vitamin d and neurology , calcium , vitamin d deficiency , chemistry , organic chemistry
SUMMARY The effect of parenteral administration of magnesium was studied in five patients with hypomagnesaemic hypocalcaemia. The initial metabolic state was characterized by a normal level of serum immunoreactive parathyroid hormone (iPTH), and by low or undetectable serum 25‐hydroxyvitamin D (25OHD) and 1,25‐dihydroxyvitamin D (1,25 (OH) 2 D). A parathyroid response was elicited by the acute intravenous injection of magnesium chloride. In contrast, 1,25(OH) 2 D did not change up to 24 h after the injection. Intramuscular magnesium sulphate restored serum magnesium and calcium to normal, whereas iPTH was transiently increased. 25OHD remained low and unchanged. 1,25(OH) 2 D rose very slowly, but the correction of hypocalcemia began before any change in 1,25(OH) 2 D levels could be demonstrated. Thus, the early correction of hypocalcemia mainly depended on the restoration of an adequate parathyroid function independently of the secretion of 1,25(OH) 2 D.